GLENMECT (Glenmark Pharmaceuticals Australia Pty Ltd)
Product name
GLENMECT
Date registered
Evaluation commenced
Decision date
Approval time
113 (255 working days)
Active ingredients
ivermectin
Registration type
New generic medicine
Indication
GLENMECT is indicated for the treatment of:
- onchocerciasis and intestinal strongyloidiasis (anguillulosis).
- crusted scabies in conjunction with topical therapy.
- human sarcoptic scabies when prior topical treatment has failed or is contraindicated.
Treatment is only justified when the diagnosis of scabies has been established clinically and/or by parasitological examination. Without formal diagnosis, treatment is not justified in case of pruritus alone.